 Director of the Forensic Services Laboratory, Fernanda Henry. The COVAX facility has commenced the COVID-19 vaccine rollout with Ghana being one of the first countries to receive vaccines. The first round of allocations provides doses of the Oxford AstraZeneca vaccine to COVAX facility participants through May 2021. This first round of allocation outlines delivery of doses of the vaccine manufactured by AstraZeneca and CoviShield licensed to and manufactured by Serum Institute of India to 142 facility participants. Chief Executive Officer of GAVI, the Vaccine Alliance Dr. Seth Berkeley highlighted what is expected in the coming weeks and months. We have to think about this in terms of doses, dollars and deliveries. Through our 190 participants in the COVAX facility, we continue to rely on the support of both self-financing participants that pay their own way through the COVAX facility, but are working together in a multilateral fashion to help bring down the cost and increase availability of vaccines and the support of donors to fund lower income economies through the GAVI COVAX Advanced Market Commitment. As you know, we made major progress at the recent G7 virtual summit on February 19th when we doubled the support for the GAVI COVAX AMC with major new funding from Germany, the European Union, the United States and a number of other donors. We also learned that France and the United Kingdom would share surplus doses with COVAX, joining other nations and contributing to what we hope will be a major new source of early vaccines. We're incredibly grateful for all this support. Dr. Berkeley explained that with the required support, the COVAX facility can secure more vaccine doses, thus allowing for the increased protection of populations of low and lower middle income countries. We believe with the right funding in place, it may be possible to purchase even more doses, maybe 1.8 billion doses of vaccine in 2021 for the low and lower middle income AMC countries. That's 500 million doses more than we set out to achieve late last year. Our goal is to protect as many people as possible and to count on the vision and support of the international community to help us achieve this. But we also count on the private sector to have not just one, but a handful of safe and effective vaccines available, as Richard mentioned, and scaled up in less than 12 months is a triumph of collaboration between science, government, and business. We're proud to be delivering this month vaccines from three manufacturers, the Serum Institute of India, AstraZeneca Oxford, and Pfizer-BioNTech. We're also excited by the progress made by the Johnson & Johnson single dose vaccine, which just received U.S. FDA emergency use authorization. And as you know, has agreed to provide us with half a billion doses. And by our recent memorandum of understanding with Novavax, which we hope to turn into a firm advance purchase agreement for 1.1 billion doses in the current weeks. Chief Executive Officer of GAVI, the Vaccine Alliance, Dr. Seth Berkeley, speaking there at a media briefing held on Tuesday on the commencement of the COVID-19 vaccine rollout by the Corvax facility.